Literature DB >> 7478589

Evidence for cell-specific differences in transformation by N-, H- and K-ras.

J Maher1, D A Baker, M Manning, N J Dibb, I A Roberts.   

Abstract

Although Ras plays a fundamental role in cellular proliferation, differentiation and transformation, clear functional differences between the three major Ras proteins (N-, H- and K-Ras) have not as yet been demonstrated. In this study, chimeric constructs were used to compare directly transformation by N-, H- and K-ras oncogenes. In Rat-2 and NIH3T3 fibroblasts, transformation assays (anchorage independence, focus-formation and growth in 1% FCS) showed that H12-Ras was more transforming than N12-Ras or K12-Ras. By contrast, in the human multipotent haemopoietic cell line, TF-1, N12-Ras exhibited greater biological activity. Northern blotting and protein analyses indicated that these findings were not the result of differences in expression or stability of p21Ras. Using further H-ras/N-ras chimeric constructs, we found that the greater transforming activity of H12-Ras in fibroblasts was not due to the hypervariable-CAAX region, but rather to unique sequences between amino acids 84 and 143. These data demonstrate cell specific differences in the intrinsic transforming potential of N-ras, H-ras and K-ras oncogenes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7478589

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  16 in total

Review 1.  Posttranslational Modifications of RAS Proteins.

Authors:  Ian Ahearn; Mo Zhou; Mark R Philips
Journal:  Cold Spring Harb Perspect Med       Date:  2018-11-01       Impact factor: 6.915

2.  Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice.

Authors:  Chaitali Parikh; Ramesh Subrahmanyam; Ruibao Ren
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

3.  Wild-type NRas and KRas perform distinct functions during transformation.

Authors:  Poppy P Fotiadou; Chiaki Takahashi; Hasan N Rajabi; Mark E Ewen
Journal:  Mol Cell Biol       Date:  2007-07-16       Impact factor: 4.272

4.  L-NAME has opposite effects on the productions of S-adenosylhomocysteine and S-adenosylmethionine in V12-H-Ras and M-CR3B-Ras pheochromocytoma cells.

Authors:  Maia Sephashvili; Elene Zhuravliova; Tamar Barbakadze; Mukhran Khundadze; Nana Narmania; David G Mikeladze
Journal:  Neurochem Res       Date:  2006-09-27       Impact factor: 3.996

5.  Functional specificity of ras isoforms: so similar but so different.

Authors:  Esther Castellano; Eugenio Santos
Journal:  Genes Cancer       Date:  2011-03

6.  Proteomic and phosphoproteomic alterations in benign, premalignant and tumor human breast epithelial cells and xenograft lesions: biomarkers of progression.

Authors:  So Hee Kim; Fred R Miller; Larry Tait; Jie Zheng; Raymond F Novak
Journal:  Int J Cancer       Date:  2009-06-15       Impact factor: 7.396

7.  Mutated K-ras(Asp12) promotes tumourigenesis in Apc(Min) mice more in the large than the small intestines, with synergistic effects between K-ras and Wnt pathways.

Authors:  Feijun Luo; David G Brooks; Hongtao Ye; Rifat Hamoudi; George Poulogiannis; Charles E Patek; Douglas J Winton; Mark J Arends
Journal:  Int J Exp Pathol       Date:  2009-10       Impact factor: 1.925

8.  Farnesyl transferase inhibitor FTI-277 inhibits breast cell invasion and migration by blocking H-Ras activation.

Authors:  Kyung Hun Lee; Minsoo Koh; Aree Moon
Journal:  Oncol Lett       Date:  2016-07-11       Impact factor: 2.967

Review 9.  Signal-transducing protein phosphorylation cascades mediated by Ras/Rho proteins in the mammalian cell: the potential for multiplex signalling.

Authors:  D T Denhardt
Journal:  Biochem J       Date:  1996-09-15       Impact factor: 3.857

Review 10.  Non-redundancy within the RAS oncogene family: insights into mutational disparities in cancer.

Authors:  Ken S Lau; Kevin M Haigis
Journal:  Mol Cells       Date:  2009-09-30       Impact factor: 5.034

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.